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Periodontal disease (PD) and Alzheimer’s disease (AD) are inflammatory conditions affecting the global adult population. In the
pathogenesis of PD, subgingival complex bacterial biofilm induces inflammation that leads to connective tissue degradation and
alveolar bone resorption around the teeth. In health, junctional epithelium seals the gingiva to the tooth enamel, thus preventing
bacteria from entering the gingivae. Chronic PD involves major pathogens (Porphyromonas gingivalis, Treponema denticola, and
Tannerella forsythia) which have an immune armoury that can circumvent host’s immune surveillance to create and maintain an
inflammatory mediator rich and toxic environment to grow and survive.The neurodegenerative condition, AD, is characterised by
poormemory and specific hallmark proteins; periodontal pathogens are increasingly being linked with this dementing condition. It
is therefore becoming important to understand associations of periodontitis with relevance to late-onset AD.The aim of this review
is to discuss the relevance of finding the keystone periodontal pathogen P. gingivalis in AD brains and its plausible contribution to
the aetiological hypothesis of this dementing condition.
1. Introduction
Organ Specific Inflammation
(a) The Oral Cavity. Bacterial diseases such as chronic peri-
odontal disease evoke the host’s immune responses, involving
both the innate and adaptive signalling mechanisms with
cell recruitment from the systemic circulation (macrophages,
plasma cells, and T and B lymphocytes) that infiltrate the
gingival soft tissues [1]. In periodontal disease (PD) there is
paucity of information concerning the molecular pathways
in the host cells, which could regulate their inflamma-
tory response to complex subgingival bacterial biofilms. In
the gingival inflammatory infiltrate, the outcome of the
cytokine/chemokine response is regulated by the production
of proinflammatory cytokines that are encountered by anti-
inflammatory cytokines [2]. Porphyromonas gingivalis (P.
gingivalis) has been proposed as the keystone periodontal
pathogen in maintaining the PD associated inflammophilic
microbiota [3, 4]. An inflammatory pathology is a disease
condition where the host’s immune defences constantly
encounter invading pathogens or bacterial virulence factors.
The host’s defence failure in the gingival tissues, leads to the
keystone inflammophilicmicrobe,P. gingivalis, colonising the
subgingival areas and subsequently disseminating to distant
organs [5–7]. The subversive armoury of this bacterium
not only provides nutritional sustenance from sustainable
inflammatory milieu but also allows for continued survival
of P. gingivalis in the highly toxic niches [8].
(b) The Brain. The brain is immunologically privileged due
to a physical blood brain barrier (BBB) and due to the
absence of a lymphatic system and therefore displays low
levels of molecules that are critical to antigen presentation.
Thus, during neurodegeneration, the brain relies less on the
recruitment of peripheral adaptive immune surveillance cells
but more on the resident central nervous system (CNS) cells
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to recognise and mount a response against the invading
pathogens. Although astrocytes and neurons have the capac-
ity to deal with infection, it is the microglial cells that serve
as the primary protective guardians of the healthy brain.
Susceptibility to microbial infection appears to increase
during advancing age and just before clinical diagnosis of
dementia is confirmed [9]. This is attributed to the fact that,
during aging, microglia appear to develop functional defects
[10]. Thus, it can be argued that where age is a known risk
factor (as in AD), infections will play a major role in the
specific disease processes leading to dementia.
2. The Oral Cavity
The oral cavity is equally important for both nutritional and
communication functions which are necessary for a healthy
and social existence in animal species as well as for bacteria
which exist in this niche. It includes a variety of specialised
structures including teeth, keratinised and non-keratinised
mucosa, gingivae, periodontal structures, salivary glands,
and specialist linings for taste. The oral cavity has its own
protective barriers to reduce colonisation of these bacteria
including the buccal, gingival, and tongue mucosal epithelial
surfaces [11]. These surfaces work together with the internal
secretions such as saliva, mucous, and the gingival crevicular
fluid to protect the epithelial membrane [12]. Saliva contains
a range of both innate and adaptive immune molecules
designed to minimise the attachment and survival of organ-
isms that may establish within the gingival surface [13].
Chemical factors such as antimicrobial peptides including
defensins (𝛼-defensins expressed in neutrophils; 𝛽-defensins
from gingival mucosa) [14–16] are an example of the innate
immune mechanisms, which are involved in controlling
pathogenic bacterial colonisation. Measures controlling the
adaptive immune response include immunoglobulins (IgA)
specific for the mucosal surfaces [17, 18] and various enzymes
(lactoferrin and lysozyme) designed to prevent bacterial
metabolic processes [19] essential for their colonisation and
lysis.
In addition, the gingival mucosa has developed a direct
protective response against bacterial antigenic challenges
through the action of cell-mediated immunity within the
periodontal structures [20, 21] via antigen presentation. This
results in the subsequent infiltration of T and B cells, a
hallmark of the host’s response to the presence of these
non host organisms [20–23]. If the balance between natural
protective barriers and bacterial colonisation is disrupted,
the bacterial load increases in favour of oral inflammatory
conditions such as PD [24] in susceptible individuals.
3. Periodontal Disease
There are two distinct inflammatory conditions that make
up PD: gingivitis, a plaque-induced, reversible condition; and
chronic periodontitis, an irreversible condition.
3.1. Gingivitis. Gingivitis represents the most prevalent dis-
ease to affect the periodontium, affecting up to 60% of
teenagers and 40–50% of adults [25]. Gingivitis is caused
by the accumulation of dental plaque and may manifest
after only days or weeks following plaque accumulation
[26], whereas periodontitis takes longer to develop [27]. To
support the aetiological link between plaque and gingivitis,
studies aiming to reduce or eliminate dental plaque have led
to disease resolution [26, 28, 29]. Differences in susceptibility
of individuals to gingivitis have been demonstrated. It has
been suggested that these differences have been down to the
microbial makeup of the plaque or the rate of plaque accu-
mulation [26]. Local factors that may encourage an increased
plaque accumulation, and therefore increase the susceptibil-
ity to gingivitis, include developmental or anatomical tooth
variations, pathological tooth conditions, caries, frenum
position, gingival developmental conditions, and iatrogenic
factors (e.g., overhangs on restorations) [28]. Systemic factors
may also contribute to an individual’s susceptibility to gin-
givitis. These include metabolic factors (e.g., puberty, preg-
nancy), genetic factors, environmental factors (e.g., smoking,
medication, and nutritional status), and systemic conditions
(neutropenia, HIV disease) [28]. More recently, the indi-
vidual’s susceptibility (irrespective of quantitative or qualita-
tive plaque accumulations) to the development of gingivitis
has been investigated. Trombelli et al. [29] experimentally
demonstrated two distinct groups, “high responders” and
“low responders.”These groups showed significantly different
severities of gingivitis to similar plaque accumulation rates.
These results reinforce the hypothesis of subject-specific
effects of poor oral hygiene on gingival tissues. Although
gingivitis does not always progress to periodontitis, it has
been shown that individuals who show an increased suscep-
tibility to gingivitis will also have an increased susceptibility
to developing periodontitis, although, to date, there are no
reliable means to predict susceptibility to periodontitis [30].
3.2. Periodontitis. Periodontitis is the most common infec-
tious inflammatory disease of humans. A recent survey in the
USA concluded that 47.2% of adults aged 30 years and older
had periodontitis [31]. Periodontitis is a chronic inflamma-
tory destruction of the gingival connective tissue attachment
to the root surface, cementum, and adjacent alveolar bone
resulting from continuous inflammatory response triggered
by subgingival bacterial biofilm.The causal bacteria typically
include P. gingivalis, Treponema denticola (T. denticola), and
Tannerella forsythia (T. forsythia) [24]. The established PD
lesion is the subgingival pocket, which has variable (5–
10mm) depth, in which 1 × 109 mixed communities of
inflammophilic bacteria can flourish around the teeth [12].
These increased numbers represent a significant bacterial
load with the loss of collagen fibers and attachment to the
cementum surface, apical migration of junctional epithelium,
formation of deep periodontal pockets, and resorption of
alveolar bone. Alveolar bone is continuously undergoing the
process of remodelling such as constant bone resorption
by osteoclasts followed by a phase of bone formation by
osteoblasts through a coupling mechanism.
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4. Inflammatory Bacterial Challenge Driving
Periodontal Disease Process
In PD, the inflammatory response is initiated by bacteria but
also involves other molecules known as pathogen associated
molecular patterns (PAMPs). These include lipopolysaccha-
ride (LPS), capsular proteins, flagellin, fimbrillin, peptido-
glycan, bacterial DNA, proteases, (gingipains, dentisilin, and
trypsin-like proteases) [32], and other protein modifying
enzymes [33], which act to both stimulate and/or dampen
the hosts’ innate immune responses [1, 33]. The stimulation
causes hosts’ pattern recognition receptors (PRRs) to produce
a range of cytokines which recruit appropriate immune
cells to the site of infection [32]. In addition, the metabolic
products of bacteria cause the periodontal pocket epithelium
to secrete neuropeptides (such as substance P, calcitonin
gene-related peptide, and vasoactive intestinal polypeptide)
that promote vasodilation of local blood vessels andpermit an
influx of neutrophils in response to signals from chemokines
[1]. The immune dampening response accompanying the
bacterial infection protects the periodontopathogen (P. gin-
givalis) by compromising the host’s innate defences in diverse
ways [33–35].
5. P. gingivalis, the Keystone Pathogen,
and Its Ability to Bypass Inflammatory
Signalling Cascades
A keystone pathogen is defined as an organism that can hold
an entire arch together [3, 36].Holding the arch can be viewed
as an essential scaffold that acts as a guardian for the survival
of new inflammophilic synergistic microbial communities
in the same ecological niche. In PD, this crucial bacterium
is said to be P. gingivalis. The metabolic dominance of this
bacterium in terms of its population in PD appears to be
maintained at low levels, perhaps to avoid direct competition
within the same species or for natural selection of a dominant
bacterium. Itsmastery at evading hosts’ immunemechanisms
to evoke and sustain inflammatory milieu via a number of
signalling cascades affords protection not only to itself but
also to other inflammophilic organisms that may be less able
to survive such toxic conditions [8].Themain innate immune
system signalling pathways for bacteria and/or their products
include the integrin receptor CR3 (CD11b/CD18) and toll-like
receptor (TLR) signalling [37] and the complement cascade
[38]. For a fuller appreciation of the complement cascade
involvement [38] in PD, see Hajishengallis et al. [4] and
Hajishengalis [37]. In brief, a functioning complement system
comprises of at least three different activation pathways
(classical, alternative, and the mannan binding lectin), all
of which converge upon the central component C3 which
then leads to the terminal pathway activation. Through this
activation process, numerous enzymatic activation fragments
are generated many of which have immunomodulatory
functions; examples of these include the anaphylatoxins C3a,
C5a and the cytolytic membrane attack complex (MAC).
There is cross talk between these pathways for cytokine
liberation, and other downstream signalling pathways such
as the extracellular signal-regulated pathways of activation
which are also fully described by Hajishengalis [37].
6. Virulence Factors of P. gingivalis
Holt et al. [39] extensively reviewed the macromolecules
associatedwithP. gingivalis that, in vivo, might function in the
inflammatory and destructive events of PD.These include the
capsule, outer membrane, its associated LPS, fimbriae, pro-
teinases, and selected enzymes. LPS is an integral component
of all bacteria and is found in the outer membrane layer. LPS
may also be found in a cell-free form occurring after bacterial
autolysis as a result of exposure to antibiotics during rapid
growth or when essential nutrients have depleted from the
environment. It is a stable molecule, which can withstand
heating to 100∘C for several hours. When in the host, main
role of LPS appears to be linked to priming of tissue specific
antigen presenting cells [40].
P. gingivalis LPS is generally of smooth type [41], con-
sisting of three regions: lipid A, R polysaccharide, and O
polysaccharide [42]. The lipid A region of LPS in many
cell types promotes antigen presenting cell (neutrophils,
dendritic cells) and activation and secretion of proinflamma-
tory cytokines and nitric oxide [43]. This can result in the
stimulation of prostaglandin and leukotriene production and
activation of the complement cascade and the coagulation
cascade [44]. Hence, high levels of LPS within the host can
result in an elevated immune response, which, once above the
hosts’ threshold level, will result in damage to the tissue [44].
P. gingivalis contains two LPS macromolecules, an O-LPS
containing the O polysaccharide attached to the lipid A core
and an A-LPS where the phosphorylated branched, mannan
repeating unit is also attached to the lipid A core [45]. In
addition, P. gingivalis LPS possesses significant amounts of
lipid A heterogeneity containing tetra- and penta-acylated
structures. The heterogeneity of LPS includes differences in
the number of phosphate groups together with both the
amount of lipid A fatty acids and their specific position. The
presence of multiple lipid A structures makes it more difficult
for the innate host responses to recognise the molecule
thereby aiding the virulence of P. gingivalis [34].
Another important factor regarding the LPS of P. gingi-
valis is its ability to modify certain surface proteins. Veith
et al. [35] demonstrated that the gingipain protease complex
from P. gingivalis W50 has an intimate association with
LPS glycosylation sites of these proteins. These glycosylation
sites give rise to the cross-reactivity between monoclonal
antibodies against LPS and to the carbohydrate moieties on
gingipains [35]. O’Brien-Simpson et al. [46] suggested that
the modification recognised by the P. gingivalis monoclonal
antibody (clone 1B5) is located in the C-terminal segment
of RgpB, suggesting that gingipains can be modified by LPS
attachment to the conserved C-terminal segment. This could
have implications in the virulence of this pathogen as it
displays a mechanism by which the gingipains attach to
the outer membrane [47]. LPS also activates the immune
response through PRRs on the membrane of host cells or
with both the tetra- and penta-acylated lipidA structures ofP.
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gingivalis. The latter differentially activate the TLR-mediated
nuclear factor kappa enhancer of B cell (NF-𝜅B) signalling
pathway. P. gingivalis LPS has been shown to use both TLR-
2 and TLR-4, depending on the cell type [48]. Bacteria also
secrete exotoxins, proteins (often enzymes and metabolic
by-products) that exert damage on the host following their
release. These PAMPs include proteases, coagulases, and
fibrinolysins, which act on their specific substrates [39, 47,
49]. For example, P. gingivalis has the ability to secrete a large
variety of enzymes such as peptidylarginine deiminase, an
enzyme which can modify free or peptide-bound arginine to
citrulline [33, 50]. Others include collagenases, which break
the peptide bonds in collagen (the main structural protein of
connective tissues) [51].
P. gingivalis is also armed with two types of gingi-
pains, lysine specific (Kgp) and arginine specific (Rgps) as
determined by the specificity for their cleaving sites [52].
Gingipains are known to play a major role in the progression
of PD, inducing inflammation and tissue destruction in the
periodontium [53].
Peptidoglycan is the only cell wall component common
to all Gram-negative and Gram-positive bacteria and is
the essential scaffold of all cell walls that provides rigid-
ity. Peptidoglycan, the major component of Gram-positive
bacterial cells, is formed of glycan strands cross-linked via
short peptides. The glycan segment comprises two alter-
nating amino-hexose sugars: N-acetylglucosamine and N-
acetyl muramic acid, cross-linked by short chains of amino
acids. Usually, L-alanine is bound to muramic acid in Gram-
positive bacteria, or mesodiaminopimelic acid in Gram-
negative bacteria [54–56]. Peptidoglycan is capable of inciting
innate immune responses in general [57, 58] and to those
that ultimately contribute to sepsis [59]. Both bacterial pep-
tidoglycan and its products (muramyl peptides) have been
shown to act as inflammatory mediators by activating host’s
innate PRR (TLRs) and intracellular signalling receptors such
as nucleotide-binding oligomerization domain or NOD 1
and NOD 2 [60]. Of these, TLR-2 is one that recognises
peptidoglycan throughMyD-88/NF-𝜅B subsequently leading
to chemokine/cytokine release [57, 58].
A genome-wide in vitro expression profile of neutrophils
[40] demonstrated that the cord blood following challenge
by the Gram-positive bacterial peptidoglycan was capable
of activating neutrophils. Neutrophil activation was detected
by expression of the integrin receptor CR3 (CD11b) and the
NF-𝜅B signalling pathway of cyto/chemokine release (TNF-
𝛼, IL-8) [40]. During the process, significant production of
reactive oxygen species (ROS) was also recorded, suggesting
that peptidoglycan may be a potential source of ROS during
an infectious episode [40].
7. Immune Evasion Strategies of P. gingivalis
Plethora of data supports the idea that P. gingivalis is a master
evader of the host’s immune system [33–35, 61–67].The struc-
tural nature of a biofilm provides a physical barrier against
immune cells of the host [68]. In addition, a number of active
mechanisms are employed by bacteria including degradation
of complement fragments (avoiding opsonisation by protease
digestion of complement fragments), recruitment of hosts’
regulatory proteins (Factor H, C4 binding protein), and
protection by the bacterial cell wall. In the latter, either the
MAC is unable to form, or their cell wall component (polysac-
charides) mediated complement activation is suppressed [63,
69–71]. P. gingivalis is very resistant to destruction by com-
plement due to the ability of the gingipains to degrade C3 and
C5 thereby preventing the deposition of C3b on the surface of
the bacterial cell walls [67, 72]. Gingipains have been found
to be modified by, and reactive with, an LPS recognising
monoclonal antibody (MAb 1B5) suggesting a mechanism
for the attachment of the RgpA and Kgp complexes to the
outer membrane [35]. This attachment potentially increases
the virulence of the bacterium, as gingipains present on the
surface of the bacterial cell wall will be readily available
to degrade complement proteins thus evading the hosts’
immune response. Gingipains can also attach to C4b binding
protein avoiding destruction by complement mediated lysis
[63].
Another immune evasion mechanism demonstrated by
P. gingivalis is its adherence to erythrocytes via complement
receptor 1 (CR1).This enables the bacteria to pass undetected
by circulating phagocytes and provide a potential transport
mechanism for the movement of P. gingivalis via the systemic
circulation [66]. The additional ability of P. gingivalis to alter
the lipid A structure of LPS could be one of the strategies
utilised to evade innate host defence in gingival tissues
potentially contributing to the pathogenesis of PD [73].
Our in-house data has demonstrated cleavage of the CD14
receptor from the neuroblastoma (IMR32) cell line during
in vitro exposure to P. gingivalis crude culture supernatant
containing abundant gingipains.
P. gingivalis strains are also capable of evading the innate
immune recognition by degrading complement component
C3 [61] and can intercept the cross talk at the C5 convertases
stage by expressing peptidylarginine deiminase enzyme to
inactivate C5a for its own survival [33].
The immune invasion strategies of P. gingivalis are of great
importance not only in PD, but also in relation to systemic
disease as this bacterium and its virulence factors access the
systemic organs. In doing so, P. gingivalis and/or its products
and any inflammatory mediators generated within the blood
can potentially reach remote body organs. Routine dental
procedures, including dental extraction, periodontal surgery,
tooth scaling, and even tooth brushing and flossing seed
oral bacteria into the systemic circulation [74–77]. Fitting
with the theory of “focal infection” periodontal bacteria have
the potential to go undetected by the immune system (via
immune evasion mechanisms) and ultimately access remote
body organs of individuals with susceptibilities for devel-
oping inflammatory pathologies. Currently, PD has been
linked directly with cardiovascular disease [78–80], diabetes
mellitus [81], respiratory infections [82, 83], rheumatoid
arthritis [84, 85], osteoporosis [86], obesity [87], and adverse
pregnancy outcomes [88] including low birth weight [89] and
pretermbirth [90].Most recently PDhas been linkedwith the
aetiology of AD [91–93].
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8. Alzheimer’s Disease:
A Neurodegenerative Disease
Proteostasis (tau and/or A𝛽 plaques) is a central component
of pathology in Alzheimer’ disease [94]. AD is characterised
by the accumulation of intracellular neurofibrillary tangles,
which are composed of microtubule binding protein tau
assembled into paired helical and straight filaments [95]
and the extracellular deposits of fibrillary A𝛽 [94]. Altered
synaptic plasticity and synaptic loss correlates with cognitive
dysfunction [96, 97]. Chronic intracerebral inflammation is
also a pivotal factor driving neurodegeneration in the form
of activated glia [98]. The amyloid hypothesis of Hardy and
Selkoe [99] relies on intracerebral factors especially A𝛽 being
pivotal toADpathogenesis. Reactive oxygen/nitrogen species
and the chronic activation of the complement cascade are
all features of AD inflammatory pathology attributed to A𝛽
deposition [98].
The “aetiological” hypothesis accounts for extrinsic
inflammatory factors contributing to the subclinical and
clinical phases of the late-onset form of AD [6, 100–105].
Evidence from genome-wide studies suggests the innate
immune system is involved in the onset of AD [106, 107]
and this supports a role for microbes and/or their immuno-
genic components that classically initiate innate immune
responses. Further evidence linking microbes to A𝛽 plaque
deposition supports the ability of this hallmark protein to act
as an antimicrobial peptide to counteract infections [108]. It
is therefore not surprising that A𝛽 functions are related to
innate immune defence mechanisms that mediate intrinsic
responses [109]. In addition, multiple systemic infections
can exacerbate premorbid cognitive status in AD patients
and the current view indicates that this is the result of
proinflammatory mediators crossing the BBB [93, 100, 101].
Poole et al. [6] reported that periodontal pathogen P.
gingivalis components are also identified in AD subjects, and
this could help to explain the associations of PD with the
onset of, and perpetuating inflammation via, the keystone
pathogen hypothesis described by Hajishengallis et al. [3]. In
terms of the time-frame of the chronicity of inflammation
of the two diseases under discussion, PD presents after 30
years of age [31], whereas the late-onset AD appears later (80+
years onwards) in life. Thus there is sufficient time for an
established chronic periodontal pathogen such as P. gingivalis
[110, 111] to exploit the haematogenous route [66] to access the
brain as illustrated by Singhrao et al. [112].
Our recent work tested the proof of concept using
ApoEnull mouse model of experimental periodontitis, where-
by mice were periodontally infected with P. gingivalis, T.
denticola, T. forsythia, and Fusobacterium nucleatum as
mono- and polybacterial infections. Following chronic gin-
gival infection and molecular identification using nucleotide
sequencing, a statistically significant number of ApoEnull
mice brains contained the P. gingivalis genomic DNA. These
results demonstrated that the periodontal pathogen P. gingi-
valis was able to access the ApoEnull mice brains [7].
As this keystone pathogen remains in low amounts (103)
in the subgingival niche, the larger brain tissue ratio to num-
ber of actual P. gingivalis cells in the dementing human brain
wouldmake it difficult to detect bymolecularmethodologies.
Given the resilience of P. gingivalis in the human host, even
the presence of fewer P. gingivalis in the brain over at least
three decades would be sufficient to contribute to a low but
persistent level of local inflammation for its own nutritional
sustenance and survival. One of the traits of a keystone
inflammophilic pathogen is to establish communities of
other microbes that can thrive under toxic inflammatory
environment and contribute further to inflammation in the
host. This could explain why specific microbes are also said
to associate with AD hallmark protein A𝛽. These include
herpes simplex virus type I [104],Chlamydophila pneumoniae
[103], and several species of spirochetes of which the well
cited ones are T. denticola and Borrelia burgdorferi [91, 105].
Activation of the complement cascade in the AD brain can
be direct via the hallmark proteins or from whole bacteria,
or their components (LPS and peptidoglycan), and indirect
activation via liberation of proinflammatory cytokines from
other (TLR) signalling cascades [103–115]. Furthermore, lib-
eration of reactive oxygen/nitrogen species also takes place
when innate immune responses are activated by A𝛽 [98] and
due to peptidoglycan from bacterial cell walls [40]. Such an
environment is conducive to these inflammophilic pathogens
in AD brains.
Our research also examined the inflammatory compo-
nent arising from the innate immune responses relating to
the dissemination of this bacterium into the brains of our
ApoEnull mouse PD model. By using antibodies against the
complement activation products of C3 convertase stage and
the membrane attack complex on brain tissue sections from
the ApoEnull mice, microglia in both infected and sham-
infected groups, demonstrated strong intracellular labelling
with C3 and C9. This was concluded as ongoing biosynthesis
bymicroglial cells because Singhrao et al. [116, 117] had previ-
ously demonstrated that, in human brain tissue sections from
another neurodegenerative condition, glia were the source of
complement whilst the in vitro study [117] demonstrated that
neurons were vulnerable from attack.Thus, from the infected
mice brains, it was clear that pyramidal neurons of the
hippocampus were opsonised with C3 activation fragments
(𝑃 = 0.032) and were likely to have been vulnerable from
activated complement [7]. The data from the human brains
and that from the in vivo mouse study suggested specific
associations of P. gingivalis with AD inflammatory pathology
[7].
9. Implications of Inflammation in the Brain
Direct implications of bacterial infections in the elderly is
said to affectmemory [9, 100] via cytokine release in response
to infection [100]. Indeed an increased amount of cytokines
especially the macrophage secreted TNF-𝛼 has been reported
in plasma of AD subjects [93]. Furthermore, elderly indi-
viduals appear to harbour a higher titre of circulating IgG
from several periodontal pathogens [118], and clinical studies
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support this to correlate with a possible onset of mild
cognitive impairment and even result in AD [119]. Persisting
chronic peripheral/intrinsic inflammation is hypothesised to
affect BBB capillary wall which likely prevents efflux of sol-
uble/insoluble A𝛽 from the CNS. This hypothesis was tested
following vaccination of anti-A𝛽 antibodies whereby amyloid
plaque A𝛽 was shown to exit the brain via the cerebral blood
vessel walls but failed and accessed the perivascular spaces
instead [120].
10. An Overview of the Role of Periodontal
Pathogens Modulating CNS Inflammation
Bacteria and/or their immunogenic components at the
appropriate concentration initiate the classical innate imm-
une signalling pathways via TLR-2 and TLR-4 mechanisms
whereby the release of cytokines by microglia (IFN-𝛾 and
TNF-𝛼) is an inevitable consequence. Chronic release of
cytokines will eventually change the permeability at the BBB
and reduce the efflux of A𝛽 from the CNS into the sys-
temic circulation [121]. Under appropriate concentrations of
LPS/peptidoglycan, TLR-2 and TLR-4 signalling, and release
of reactive oxygen/nitrogen species such as superoxide ions,
iNOS/NO, cytokine secretion and bacterial activation of
the complement system become inseparable. Together these
factors lead to vital neurons being destroyed and enhanced
maintenance of chronic inflammation with consequences for
development of disease [98, 113, 122–125]. Inheritable inflam-
matory traits related to cytokines exist within our population
and especially in the decedents of those having suffered
from the late-onset AD [126]. Thus, all immunogens that
initiate innate immune responses of the host resulting in the
liberation of proinflammatory cytokines may be detrimental
in the individuals with inflammatory susceptibility traits.
11. Conclusions
Periodontal disease(s) are among the most common chronic
infections of humans, characterized by the loss of periodontal
ligament, connective tissue, and alveolar bone, and are a
major cause of tooth loss. Major periodontal pathogens lead
to chronic systemic inflammation due to recurrent transient
bacteraemia, resulting in high levels of systemic cytokines
and chemokines. Multiple epidemiological, clinical, and
molecular studies have shown that PD associated chronic
inflammation is associated with increased risk of dementia,
including AD. Recently, an in vivo study in ApoEnull mice
periodontally infected with P. gingivalis demonstrated the
presence of P. gingivalis bacterial genomic DNA in the brain
and activated the complement cascade [7]. The keystone
hypothesis of Hajishengallis et al. [3] helps to explain the
contribution that P. gingivalis may cause the early develop-
ment of a neurodegenerative condition such as Alzheimer’s
disease. In our view, P. gingivalis (highly virulent strains)
access the CNS during healthy stages but only those indi-
viduals with inflammatory susceptibility traits are likely to
develop progressive inflammatory component representing
neurodegenerative disease processes. Thus, P. gingivalis may
be a missing link that, in time, will reveal if infection driven
inflammation represents the early stage in the development of
AD pathology followed by appearance of hallmark proteins.
Disclosure
Sophie Poole recently completed her Ph.D. supervised by
StJohn Crean, Sim K. Singhrao, and Lakshmyya Kesavalu.
Alice Harding has recently completed her M.Sc on the same
subject but from the clinical aspects.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Authors’ Contribution
Lakshmyya Kesavalu, Sim K. Singhrao, and StJohn Crean
have an established collaboration on the subject of this review
article. Jointly everyone has contributed to the data and
basis of the content of this paper and has written their
section of expertise. Lakshmyya Kesavalu and StJohn Crean
contributed equally.
Acknowledgments
This review was supported by the NIH National Institute
for Dental and Craniofacial Research (R01DE020820; Dr.
Kesavalu). The work performed in the UK was fully funded
by the University of Central Lancashire.
References
[1] E. J. Ohlrich, M. P. Cullinan, and G. J. Seymour, “The
immunopathogenesis of periodontal disease,”AustralianDental
Journal, vol. 54, no. s1, pp. S2–S10, 2009.
[2] F. Ghannad, D. Nica, M. I. G. Fulle et al., “Absence of 𝛼v𝛽6
integrin is linked to initiation and progression of periodontal
disease,” The American Journal of Pathology, vol. 172, no. 5, pp.
1271–1286, 2008.
[3] G. Hajishengallis, R. P. Darveau, and M. A. Curtis, “The
keystone-pathogen hypothesis,” Nature Reviews Microbiology,
vol. 10, no. 10, pp. 717–725, 2012.
[4] G. Hajishengallis, T. Abe, T. Maekawa, E. Hajishengallis, and J.
D. Lambris, “Role of complement in host-microbe homeostasis
of the periodontium,” Seminars in Immunology, vol. 25, no. 1, pp.
65–72, 2013.
[5] I. M. Velsko, S. S. Chukkapalli, M. F. Rivera et al., “Active
invasion of oral and aortic tissues by Porphyromonas gingivalis
in mice causally links periodontitis and atherosclerosis,” PLoS
ONE, vol. 9, no. 5, Article ID e97811, 2014.
[6] S. Poole, S. K. Singhrao, L. Kesavalu, M. A. Curtis, and S.
Crean, “Determining the presence of periodontopathic viru-
lence factors in short-term postmortem Alzheimer’s disease
brain tissue,” Journal of Alzheimer’s Disease, vol. 36, no. 4, pp.
665–677, 2013.
Mediators of Inflammation 7
[7] S. Poole, S. K. Singhrao, S. Chukkapalli et al., “Active invasion
of an oral bacterium and infection-induced complement acti-
vation in ApoEnull mice brains,” Journal of Alzheimer's Disease,
vol. 43, pp. 67–80, 2015.
[8] G. Hajishengallis, “The inflammophilic character of the
periodontitis-associated microbiota,” Molecular Oral Micro-
biology, vol. 29, no. 6, pp. 248–257, 2014.
[9] N. Dunn, M. Mullee, H. Perry, and C. Holmes, “Association
between dementia and infectious disease: evidence from a case-
control study,” Alzheimer Disease and Associated Disorders, vol.
19, no. 2, pp. 91–94, 2005.
[10] K. I. Mosher and T. Wyss-Coray, “Microglial dysfunction in
brain aging and Alzheimer’s disease,” Biochemical Pharmacol-
ogy, vol. 88, no. 4, pp. 594–604, 2014.
[11] P. D. Marsh, “Dental plaque as a microbial biofilm,” Caries
Research, vol. 38, no. 3, pp. 204–211, 2004.
[12] W. J. Loesche and D. E. Lopatin, “Interactions between peri-
odontal disease, medical diseases and immunity in the older
individual,” Periodontology 2000, vol. 16, no. 1, pp. 80–105, 1998.
[13] T. K. Fa´bia´n, P. Hermann, A. Beck, P. Feje´rdy, and G. Fa´bia´n,
“Salivary defense proteins: their network and role in innate
and acquired oral immunity,” International Journal of Molecular
Sciences, vol. 13, no. 4, pp. 4295–4320, 2012.
[14] S.-U. Gorr and M. Abdolhosseini, “Antimicrobial peptides and
periodontal disease,” Journal of Clinical Periodontology, vol. 38,
no. 11, pp. 126–141, 2011.
[15] W. O. Chung and J. Y. An, “Periodontal disease and gingival
innate immunity—who has the upper hand?” in Periodontal
Diseases—AClinician’s Guide, J. Manakil, Ed., chapter 3, InTech,
2012.
[16] Q. Lu, L. Jin, R. P. Darveau, and L. P. Samaranayake, “Expression
of human 𝛽-defensins-1 and -2 peptides in unresolved chronic
periodontitis,” Journal of Periodontal Research, vol. 39, no. 4, pp.
221–227, 2004.
[17] D. F. Kinane, P. Hodge, J. Eskdale, R. Ellis, and G. Gallagher,
“Analysis of genetic polymorphisms at the interleukin-10 and
tumour necrosis factor loci in early-onset periodontitis,” Journal
of Periodontal Research, vol. 34, no. 7, pp. 379–386, 1999.
[18] M. F. Cole, S. P. Fitzsimmons, M. J. Sheridan, and Y. Xu,
“Humoral immunity to commensal oral bacteria: Quantitation,
specificity and avidity of serum IgG and IgM antibodies reactive
with Actinobacillus actinomycetemcomitans in children,”Micro-
biology and Immunology, vol. 39, no. 8, pp. 591–598, 1995.
[19] H.-F. Bu, X. Wang, Y.-Q. Zhu et al., “Lysozyme-modified
probiotic components protect rats against polymicrobial sepsis:
role of macrophages and cathelicidin-related innate immunity,”
Journal of Immunology, vol. 177, no. 12, pp. 8767–8776, 2006.
[20] F. Arenzana-Seisdedos, J. L. Virelizier, andW. Fiers, “Interferons
as macrophage-activating factors. III. Preferential effects of
interferon-𝛾 on the interleukin 1 secretory potential of fresh or
aged human monocytes,” The Journal of Immunology, vol. 134,
no. 4, pp. 2444–2448, 1985.
[21] M. A. Taubman and T. Kawai, “Involvement of T-lymphocytes
in periodontal disease and in direct and indirect induction of
bone resorption,” Critical Reviews in Oral Biology & Medicine,
vol. 12, no. 2, pp. 125–135, 2001.
[22] R. Medzhitov, “Recognition of microorganisms and activation
of the immune response,” Nature, vol. 449, no. 7164, pp. 819–
826, 2007.
[23] Y. Kumagai, O. Takeuchi, and S. Akira, “Pathogen recognition
by innate receptors,” Journal of Infection and Chemotherapy, vol.
14, no. 2, pp. 86–92, 2008.
[24] S. S. Socransky and A. D. Haffajee, “The bacterial etiology of
destructive periodontal disease: current concepts,” Journal of
Periodontology, vol. 63, no. 4, pp. 322–331, 1992.
[25] L. J. Brown and H. Lo¨e, “Prevalence, extent, severity and
progression of periodontal disease,” Periodontology 2000, vol. 2,
pp. 57–71, 1993.
[26] H. Loe, E. Theilade, and S. B. Jensen, “Experimental gingivitis
in man,” Journal of Periodontology, vol. 36, pp. 177–187, 1965.
[27] J. Lindhe, S. E. Hamp, and H. Loe, “Experimental periodontitis
in the Beagle dog,” Journal of Periodontal Research, vol. 8, no. 1,
pp. 1–10, 1973.
[28] D. N. Tatakis and L. Trombelli, “Modulation of clinical expres-
sion of plaque-induced gingivitis: I. Background review and
rationale,” Journal of Clinical Periodontology, vol. 31, no. 4, pp.
229–238, 2004.
[29] L. Trombelli, C. Scapoli, E. Orlandini, M. Tosi, S. Bottega, and
D. N. Tatakis, “Modulation of clinical expression of plaque-
induced gingivitis: III. Response of ‘high responders’ and ‘low
responders’ to therapy,” Journal of Clinical Periodontology, vol.
31, no. 4, pp. 253–259, 2004.
[30] L. Trombelli, “Susceptibility to gingivitis: a way to predict
periodontal disease?”Oral Health and Preventive Dentistry, vol.
2, no. 1, pp. 265–269, 2004.
[31] P. I. Eke, B. A. Dye, L. Wei, G. O. Thornton-Evans, and R.
J. Genco, “Prevalence of periodontitis in adults in the united
states: 2009 and 2010,” Journal of Dental Research, vol. 91, no.
10, pp. 914–920, 2012.
[32] T. Kawai and S. Akira, “Pathogen recognition with Toll-like
receptors,” Current Opinion in Immunology, vol. 17, no. 4, pp.
338–344, 2005.
[33] E. Bielecka, C. Scavenius, T. Kantyka, M. Jusko, and D.
Mizgalska, “Peptidyl arginine deiminase from Porphyromonas
gingivalis abolishes anaphylatoxin C5a activity,” The Journal of
Biological Chemistry, vol. 289, no. 47, pp. 32481–32487, 2014.
[34] R. A. Reife, S. R. Coats, M. Al-Qutub et al., “Porphyromonas
gingivalis lipopolysaccharide lipid A heterogeneity: differential
activities of tetra- and penta-acylated lipid A structures on E-
selectin expression and TLR4 recognition,” Cellular Microbiol-
ogy, vol. 8, no. 5, pp. 857–868, 2006.
[35] P. D. Veith, G. H. Talbo, N. Slakeski et al., “Major outer
membrane proteins and proteolytic processing of RgpA and
Kgp of Porphyromonas gingivalis W50,” Biochemical Journal,
vol. 363, no. 1, pp. 105–115, 2002.
[36] R. P. Darveau, G. Hajishengallis, and M. A. Curtis, “Por-
phyromonas gingivalis as a potential community activist for
disease,” Journal of Dental Research, vol. 91, no. 9, pp. 816–820,
2012.
[37] G. Hajishengalis, “Complement and periodontitis,” Biochemical
Pharmacology, vol. 80, no. 12, pp. 1992–2001, 2010.
[38] D. Ricklin, G. Hajishengallis, K. Yang, and J. D. Lambris,
“Complement: a key system for immune surveillance and
homeostasis,” Nature Immunology, vol. 11, no. 9, pp. 785–797,
2010.
[39] S. C. Holt, L. Kesavalu, S. Walker, and C. A. Genco, “Virulence
factors of Porphyromonas gingivalis,” Periodontology 2000, vol.
20, no. 1, pp. 168–238, 1999.
[40] O. N. Fong, K. Y. Y. Chan, K. T. Leung et al., “Expression profile
of cord blood neutrophils and dysregulation of HSPA1A and
OLR1 upon challenge by bacterial peptidoglycan,” Journal of
Leukocyte Biology, vol. 95, no. 1, pp. 169–178, 2014.
8 Mediators of Inflammation
[41] D. S. Kabanov and I. R. Prokhorenko, “Structural analysis of
lipopolysaccharides fromgram-negative bacteria,”Biochemistry
(Moscow), vol. 75, no. 4, pp. 383–404, 2010.
[42] C. R. H. Raetz and C. Whitfield, “Lipopolysaccharide endotox-
ins,” Annual Review of Biochemistry, vol. 71, pp. 635–700, 2002.
[43] B. Beutler, K. Hoebe, X. Du, and R. J. Ulevitch, “How we detect
microbes and respond to them: the Toll-like receptors and their
transducers,” Journal of Leukocyte Biology, vol. 74, no. 4, pp.
479–485, 2003.
[44] M. A. Taubman, P. Valverde, X. Han, and T. Kawai, “Immune
response: they key to bone resorption in periodontal disease,”
Journal of Periodontology, vol. 76, no. 11, pp. 2033–2041, 2005.
[45] M. Rangarajan, J. Aduse-Opoku, N. Paramonov et al., “Iden-
tification of a second lipopolysaccharide in Porphyromonas
gingivalisW50,” Journal of Bacteriology, vol. 190, no. 8, pp. 2920–
2932, 2008.
[46] N. M. O’Brien-Simpson, P. D. Veith, S. G. Dashper, and E. C.
Reynolds, “Porphyromonas gingivalis gingipains: themolecular
teeth of amicrobial vampire,”Current Protein& Peptide Science,
vol. 4, no. 6, pp. 409–426, 2003.
[47] L. Sandholm, “Proteases and their inhibitors in chronic inflam-
matory periodontal disease,” Journal of Clinical Periodontology,
vol. 13, no. 1, pp. 19–26, 1986.
[48] L. Kocgozlu, R. Elkaim, H. Tenenbaum, and S. Werner, “Vari-
able cell responses to P. gingivalis lipopolysaccharide,” Journal
of Dental Research, vol. 88, no. 8, pp. 741–745, 2009.
[49] C. G. Daly, G. J. Seymour, and J. B. Kieser, “Bacterial endotoxin:
a role in chronic inflammatory periodontal disease?” Journal of
Oral Pathology & Medicine, vol. 9, no. 1, pp. 1–15, 1980.
[50] E. A. V. Moelants, G. Loozen, A. Mortier et al., “Citrullination
and proteolytic processing of chemokines by Porphyromonas
gingivalis,” Infection and Immunity, vol. 82, no. 6, pp. 2511–2519,
2014.
[51] J. Travis, R. Pike, T. Imamura, and J. Potempa, “Porphyromonas
gingivalis proteinases as virulence factors in the development of
periodontitis,” Journal of Periodontal Research, vol. 32, no. 1, pp.
120–125, 1997.
[52] T. Imamura, “The role of gingipains in the pathogenesis of
periodontal disease,” Journal of Periodontology, vol. 74, no. 1, pp.
111–118, 2003.
[53] K. Miyachi, K. Ishihara, R. Kimizuka, and K. Okuda, “Arg-
gingipain a DNA vaccine prevents alveolar bone loss in mice,”
Journal of Dental Research, vol. 86, no. 5, pp. 446–450, 2007.
[54] C. Thiemermann, “Interactions between lipoteichoic acid and
peptidoglycan from Staphylococcus aureus: a structural and
functional analysis,” Microbes and Infection, vol. 4, no. 9, pp.
927–935, 2002.
[55] J. M. Ghuysen, “Use of bacteriolytic enzymes in determination
of wall structure and their role in cell metabolism,” Bacteriolog-
ical Reviews, vol. 32, no. 4, pp. 425–464, 1968.
[56] J.-M. Ghuysen and J. L. Strominger, “Sturcture of the cell wall
of Staphylococcus aureus, strain copenhages. II. Separation and
structure of disaccharides,” Biochemistry, vol. 2, no. 5, pp. 1119–
1125, 1963.
[57] T. Balamayooran, G. Balamayooran, and S. Jeyaseelan, “Toll-
like receptors and NOD-like receptors in pulmonary antibac-
terial immunity,” Innate Immunity, vol. 16, no. 3, pp. 201–210,
2010.
[58] A.-K. Ekman and L. O. Cardell, “The expression and function
of Nod-like receptors in neutrophils,” Immunology, vol. 130, no.
1, pp. 55–63, 2010.
[59] H. Kumar, T. Kawai, and S. Akira, “Pathogen recognition in the
innate immune response,” Biochemical Journal, vol. 420, no. 1,
pp. 1–16, 2009.
[60] M. T. Sorbara and D. J. Philpott, “Peptidoglycan: a critical
activator of the mammalian immune system during infection
and homeostasis,” Immunological Reviews, vol. 243, no. 1, pp.
40–60, 2011.
[61] H. A. Schenkein, “Failure of Bacteroides gingivalis W83 to
accumulate bound C3 following opsonization with serum,”
Journal of Periodontal Research, vol. 24, no. 1, pp. 20–27, 1989.
[62] R. J. Lamont and H. F. Jenkinson, “Life below the gum line:
pathogenic mechanisms of Porphyromonas gingivalis,”Microbi-
ology and Molecular Biology Reviews, vol. 62, no. 4, pp. 1244–
1263, 1998.
[63] M. Potempa, J. Potempa, M. Okroj et al., “Binding of comple-
ment inhibitor C4b-binding protein contributes to serum resis-
tance of Porphyromonas gingivalis,”The Journal of Immunology,
vol. 181, no. 8, pp. 5537–5544, 2008.
[64] H. Mahtout, F. Chandad, J. M. Rojo, and D. Grenier, “Por-
phyromonas gingivalis mediates the shedding and proteolysis
of complement regulatory protein CD46 expressed by oral
epithelial cells,”Oral Microbiology and Immunology, vol. 24, no.
5, pp. 396–400, 2009.
[65] J. Potempa and R. N. Pike, “Corruption of innate immunity by
bacterial proteases,” Journal of Innate Immunity, vol. 1, no. 2, pp.
70–87, 2009.
[66] D. Belstrøm, P.Holmstrup,C.Damgaard et al., “The atherogenic
bacterium Porphyromonas gingivalis evades circulating phago-
cytes by adhering to erythrocytes,” Infection and Immunity, vol.
79, no. 4, pp. 1559–1565, 2011.
[67] J. M. Slaney, A. Gallagher, J. Aduse-Opoku, K. Pell, and M. A.
Curtis, “Mechanisms of resistance of Porphyromonas gingivalis
to killing by serum complement,” Infection and Immunity, vol.
74, no. 9, pp. 5352–5361, 2006.
[68] S. S. Socransky and A. D. Haffajee, “Dental biofilms: difficult
therapeutic targets,” Periodontology 2000, vol. 28, no. 1, pp. 12–
55, 2002.
[69] S. A. Thompson, “Campylobacter surface-layers (S-layers) and
immune evasion,” Annals of Periodontology, vol. 7, no. 1, pp. 43–
53, 2002.
[70] J. V. Mcdowell, J. Frederick, D. P. Miller et al., “Identification
of the primary mechanism of complement evasion by the
periodontal pathogen, Treponema denticola,” Molecular Oral
Microbiology, vol. 26, no. 2, pp. 140–149, 2011.
[71] N. Shimotahira, Y. Oogai, M. Kawada-Matsuo et al., “The sur-
face layer ofTannerella forsythia contributes to serum resistance
and oral bacterial coaggregation,” Infection and Immunity, vol.
81, no. 4, pp. 1198–1206, 2013.
[72] K. Popadiak, J. Potempa,K. Riesbeck, andA.M.Blom, “Biphasic
effect of gingipains from Porphyromonas gingivalis on the
human complement system,” The Journal of Immunology, vol.
178, no. 11, pp. 7242–7250, 2007.
[73] T. D. K. Herath, R. P. Darveau, C. J. Seneviratne, C.-Y. Wang, Y.
Wang, and L. Jin, “Tetra- and penta-acylated lipid A strucures
of Porphyromonas gingivlis LPS differentially activate TLR4-
mediated NF-𝜅B signal transduction cascade and immune-
inflammaory response in human gingival fibroblasts,” PLoS
ONE, vol. 8, no. 3, Article ID e58496, 2013.
[74] L. Forner, T. Larsen, M. Kilian, and P. Holmstrup, “Incidence
of bacteremia after chewing, tooth brushing and scaling in
individuals with periodontal inflammation,” Journal of Clinical
Periodontology, vol. 33, no. 6, pp. 401–407, 2006.
Mediators of Inflammation 9
[75] L. Savarrio, D. Mackenzie, M. Riggio, W. P. Saunders, and
J. Bagg, “Detection of bacteraemias during non-surgical root
canal treatment,” Journal of Dentistry, vol. 33, no. 4, pp. 293–303,
2005.
[76] C. G. Daly, D. H. Mitchell, J. E. Highfield, D. E. Grossberg, and
D. Stewart, “Bacteremia due to periodontal probing: a clinical
and microbiological investigation,” Journal of Periodontology,
vol. 72, no. 2, pp. 210–214, 2001.
[77] I. Toma´s, M. A´lvarez, J. Limeres, C. Potel, J. Medina, and P. Diz,
“Prevalence, duration and aetiology of bacteraemia following
dental extractions,”Oral Diseases, vol. 13, no. 1, pp. 56–62, 2007.
[78] K. J. Mattila, M. S. Nieminen, V. V. Valtonen et al., “Association
between dental health and acute myocardial infarction,” British
Medical Journal, vol. 298, no. 6676, pp. 779–781, 1989.
[79] F. DeStefano, R. F. Anda, H. S. Kahn, D. F. Williamson, and C.
M. Russell, “Dental disease and risk of coronary heart disease
and mortality,” British Medical Journal, vol. 306, no. 6879, pp.
688–691, 1993.
[80] P. B. Lockhart, A. F. Bolger, P. N. Papapanou et al., “Periodontal
disease and atherosclerotic vascular disease: does the evidence
support an independent association?: a scientific statement
from the American Heart Association,”Circulation, vol. 125, no.
20, pp. 2520–2544, 2012.
[81] A. Bascones-Martinez, P. Matesanz-Perez, M. Escribano-
Bermejo, M.-A´. Gonza´lez-Moles, J. Bascones-Ilundain, and J.-
H. Meurman, “Periodontal disease and diabetes—review of the
literature,” Medicina Oral, Patologia Oral y Cirugia Bucal, vol.
16, no. 6, pp. 722–729, 2011.
[82] F. A. Scannapieco, G. D. Papandonatos, and R. G. Dunford,
“Associations between oral conditions and respiratory disease in
a national sample survey population,” Annals of Periodontology,
vol. 3, no. 1, pp. 251–256, 1998.
[83] F. A. Scannapieco, “Role of oral bacteria in respiratory infec-
tion,” Journal of Periodontology, vol. 70, no. 7, pp. 793–802, 1999.
[84] K. Tolo and L. Jorkjend, “Serum antibodies and loss of peri-
odontal bone in patients with rheumatoid arthritis,” Journal of
Clinical Periodontology, vol. 17, no. 5, pp. 288–291, 1990.
[85] C. Gleissner, B. Willershausen, U. Kaesser, and W. W. Bolten,
“The role of risk factors for periodontal disease in patients with
rheumatoid arthritis,” European Journal of Medical Research,
vol. 3, no. 8, pp. 387–392, 1998.
[86] M.K. Jeffcoat, “Osteoporosis: a possiblemodifying factor in oral
bone loss,” Annals of Periodontology, vol. 3, no. 1, pp. 312–321,
1998.
[87] J. Suvan, F. D’Aiuto, D. R. Moles, A. Petrie, and N. Donos,
“Association between overweight/obesity and periodontitis in
adults. A systematic review,” Obesity Reviews, vol. 12, no. 501,
pp. e381–e404, 2011.
[88] S. Offenbacher, H. L. Jared, P. G. O’Reilly et al., “Potential
pathogenic mechanisms of periodontitis associated pregnancy
complications,” Annals of Periodontology, vol. 3, no. 1, pp. 233–
250, 1998.
[89] S. Offenbacher, V. Katz, G. Fertik et al., “Periodontal infection
as a possible risk factor for preterm low birth weight,” Journal of
Periodontology, vol. 67, no. 10, pp. 1103–1113, 1996.
[90] M. Jeffcoat, S. Parry, M. Sammel, B. Clothier, A. Catlin, and G.
MacOnes, “Periodontal infection and preterm birth: successful
periodontal therapy reduces the risk of preterm birth,” BJOG,
vol. 118, no. 2, pp. 250–256, 2011.
[91] G. Riviere, K. H. Riviere, and K. S. Smith, “Molecular and
immunological evidence of oral Treponema in the human
brain and their association with Alzheimer’s disease,” Oral
Microbiology and Immunology, vol. 17, no. 2, pp. 113–118, 2002.
[92] P. S. Stein, M. Desrosiers, S. J. Donegan, J. F. Yepes, and R. J.
Kryscio, “Tooth loss, dementia and neuropathology in the Nun
Study,”The Journal of the American Dental Association, vol. 138,
no. 10, pp. 1314–1322, 2007.
[93] A. R. Kamer, R. G. Craig, E. Pirraglia et al., “TNF-𝛼 and
antibodies to periodontal bacteria discriminate between Alz-
heimer’s disease patients and normal subjects,” Journal of
Neuroimmunology, vol. 216, no. 1-2, pp. 92–97, 2009.
[94] H. Braak and E. Braak, “Neuropathological stageing of
Alzheimer-related changes,” Acta Neuropathologica, vol. 82, no.
4, pp. 239–259, 1991.
[95] J. Q. Trojanowski,M. L. Schmidt, R.-W. Shin, G. T. Bramblett, D.
Rao, and V. M.-Y. Lee, “Altered tau and neurofilament proteins
in neuro-degenerative diseases: diagnostic implications for
alzheimer’s disease and lewy body dementias,” Brain Pathology,
vol. 3, no. 1, pp. 45–54, 1993.
[96] R. D. Terry, E. Masliah, D. P. Salmon et al., “Physical basis of
cognitive alterations in Alzheimer’s disease: synapse loss is the
major correlate of cognitive impairment,” Annals of Neurology,
vol. 30, no. 4, pp. 572–580, 1991.
[97] E. Masliah, A. Miller, and R. D. Terry, “The synaptic orga-
nization of the neocortex in Alzheimer’s disease,” Medical
Hypotheses, vol. 41, no. 4, pp. 334–340, 1993.
[98] H. Akiyama, S. Barger, S. Barnum et al., “Inflammation and
Alzheimers disease,” Inflammation and Alzheimer’s disease, vol.
21, no. 3, pp. 383–421, 2000.
[99] J. Hardy and D. J. Selkoe, “The amyloid hypothesis of
Alzheimer’s disease: progress and problems on the road to
therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002.
[100] C. Holmes, M. El-Okl, A. L. Williams, C. Cunningham, D.
Wilcockson, and V. H. Perry, “Systemic infection, interleukin
1𝛽, and cognitive decline in Alzheimer’s disease,” Journal of
Neurology Neurosurgery & Psychiatry, vol. 74, no. 6, pp. 788–
789, 2003.
[101] C. Holmes, C. Cunningham, E. Zotova et al., “Systemic
inflammation and disease progression in Alzheimer disease,”
Neurology, vol. 73, no. 10, pp. 768–774, 2009.
[102] A. R. Kamer, R. G. Craig, A. P. Dasanayake,M. Brys, L. Glodzik-
Sobanska, and M. J. de Leon, “Inflammation and Alzheimer’s
disease: possible role of periodontal diseases,” Alzheimer’s &
Dementia, vol. 4, no. 4, pp. 242–250, 2008.
[103] B. J. Balin, C. S. Little, C. J. Hammond et al., “Chlamydophila
pneumoniae and the etiology of late-onset Alzheimer’s disease,”
Journal of Alzheimer’s Disease, vol. 13, no. 4, pp. 371–380, 2008.
[104] R. F. Itzhaki and M. A. Wozniak, “Herpes simplex virus type 1
inAlzheimer’s disease: the enemywithin,” Journal of Alzheimer’s
Disease, vol. 13, no. 4, pp. 393–405, 2008.
[105] J. Miklossy, “Chronic inflammation and amyloidogenesis in
Alzheimer’s disease—role of spirochetes,” Journal of Alzheimer’s
Disease, vol. 13, no. 4, pp. 381–391, 2008.
[106] J. C. Lambert, S. Heath, G. Even et al., “Genome-wide associ-
ation study identifies variants at CLU and CR1 associated with
Alzheimer’s disease,” Nature Genetics, vol. 41, no. 10, pp. 1094–
1099, 2009.
[107] D. Harold, R. Abraham, P. Hollingworth et al., “Erratum:
Genome-wide association study identifies variants at CLU and
PICALM associated with Alzheimer’s disease,”Nature Genetics,
vol. 41, no. 10, p. 1156, 2009.
10 Mediators of Inflammation
[108] S. J. Soscia, J. E. Kirby, K. J. Washicosky et al., “The Alzheimer’s
disease-associated amyloid 𝛽-protein is an antimicrobial pep-
tide,” PLoS ONE, vol. 5, no. 3, Article ID e9505, 2010.
[109] M. Zaiou, “Multifunctional antimicrobial peptides: therapeu-
tic targets in several human diseases,” Journal of Molecular
Medicine, vol. 85, no. 4, pp. 317–329, 2007.
[110] J. Slots and R. J. Genco, “Black-pigmented Bacteroides species,
Capnocytophaga species, and Actinobacillus actinomycetem-
comitans in human periodontal disease: virulence factors in
colonization, survival, and tissue destruction,” Journal of Dental
Research, vol. 63, no. 3, pp. 412–421, 1984.
[111] J. Slots and M. A. Listgarten, “Bacteroides gingivalis, bac-
teroides intermedius and actinobacillus actinomycetemcomi-
tans in human periodontal diseases,” Journal of Clinical Peri-
odontology, vol. 15, no. 2, pp. 85–93, 1988.
[112] S. K. Singhrao, A. Harding, T. Simmons, S. Robinson, L.
Kesavalu, and S. Crean, “Oral inflammation, tooth loss, risk fac-
tors, and association with progression of Alzheimer’s disease,”
Journal of Alzheimer’s Disease, vol. 42, no. 3, pp. 723–737, 2014.
[113] U.-K. Hanisch, “Microglia as a source and target of cytokines,”
Glia, vol. 40, no. 2, pp. 140–155, 2002.
[114] B. P. Morgan and P. Gasque, “Expression of complement in the
brain: role in health and disease,” Immunology Today, vol. 17, no.
10, pp. 461–466, 1996.
[115] M. Matsushita, S. Thiel, J. C. Jensenius, I. Terai, and T. Fujita,
“Proteolytic activities of two types of mannose-binding lectin-
associated serine protease,”The Journal of Immunology, vol. 165,
no. 5, pp. 2637–2642, 2000.
[116] S. K. Singhrao, J. W. Neal, B. P. Morgan, and P. Gasque,
“Increased complement biosynthesis by microglia and comple-
ment activation on neurons in Huntington’s disease,” Experi-
mental Neurology, vol. 159, no. 2, pp. 362–376, 1999.
[117] S. K. Singhrao, J. W. Neal, N. K. Rushmere, B. P. Morgan,
and P. Gasque, “Spontaneous classical pathway activation and
deficiency of membrane regulators render human neurons
susceptible to complement lysis,” The American Journal of
Pathology, vol. 157, no. 3, pp. 905–918, 2000.
[118] P. S. Sparks Stein,M. J. Steffen, C. Smith et al., “Serumantibodies
to periodontal pathogens are a risk factor for Alzheimer’s
disease,” Alzheimer’s and Dementia, vol. 8, no. 3, pp. 196–203,
2012.
[119] K. Okuda, T. Kato, Y. Naito, M. Ono, Y. Kikuchi, and I. Takazoe,
“Susceptibility of Bacteroides gingivalis to bactericidal activity
of human serum,” Journal of Dental Research, vol. 65, no. 7, pp.
1024–1027, 1986.
[120] C. Holmes, D. Boche, D. Wilkinson et al., “Long-term effects
of A𝛽42 immunisation in Alzheimer’s disease: follow-up of a
randomised, placebo-controlled phase I trial,” The Lancet, vol.
372, no. 9634, pp. 216–223, 2008.
[121] R. O. Weller, D. Boche, and J. A. R. Nicoll, “Microvasculature
changes and cerebral amyloid angiopathy inAlzheimer’s disease
and their potential impact on therapy,” Acta Neuropathologica,
vol. 118, no. 1, pp. 87–102, 2009.
[122] N. Laflamme and S. Rivest, “Toll-like receptor 4: the missing
link of the cerebral innate immune response triggered by
circulating gram-negative bacterial cell wall components,” The
FASEB Journal, vol. 15, no. 1, pp. 155–163, 2001.
[123] J. K. Olson and S. D. Miller, “Microglia initiate central nervous
system innate and adaptive immune responses throughmultiple
TLRs,”The Journal of Immunology, vol. 173, no. 6, pp. 3916–3924,
2004.
[124] P. Gasque, “Complement: a unique innate immune sensor for
danger signals,”Molecular Immunology, vol. 41, no. 11, pp. 1089–
1098, 2004.
[125] L. Qin, G. Li, X. Qian et al., “Interactive role of the toll-
like receptor 4 and reactive oxygen species in LPS-induced
microglia activation,” Glia, vol. 52, no. 1, pp. 78–84, 2005.
[126] E. van Exel, P. Eikelenboom, H. Comijis et al., “Vascular factors
and markers of inflammation in offspring with a parental
history of late-onset Alzheimer disease,” Archives of General
Psychiatry, vol. 66, no. 11, pp. 1263–1270, 2009.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
